Selinexor for Refractory Multiple Myeloma

Affiliations

Comment

Kenar D Jhaveri et al. N Engl J Med. 2019.

. 2019 Nov 14;381(20):1977.

doi: 10.1056/NEJMc1912625.

¹ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY kdj200@gmail.com.

No abstract available

Comment in

Selinexor for Refractory Multiple Myeloma. Reply.
Chari A, Vogl DT, Jagannath S. Chari A, et al. N Engl J Med. 2019 Nov 14;381(20):1977-1978. doi: 10.1056/NEJMc1912625. N Engl J Med. 2019. PMID: 31722163 No abstract available.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.